Workflow
Itepekimab Failure A Setback For Sanofi And Regeneron
Seeking Alphaยท2025-05-30 18:10

Group 1 - Sanofi and Regeneron Pharmaceuticals announced that itepekimab met the primary endpoint in only one of the two phase 3 trials, leading to a decline in their share prices [2] - The companies are involved in a partnership for the development of itepekimab, which is a significant product in their pipeline [2] Group 2 - The article emphasizes the importance of tracking portfolio stocks and highlights the Growth Stock Forum as a resource for identifying attractive risk/reward situations [1] - The Growth Stock Forum features a model portfolio of 15-20 names, a top picks list of up to 10 stocks, and trading ideas targeting short-term and medium-term moves [1]